Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 40Cisplatin 32Radiotherapy 22Cetuximab 22Radiotherapy, Intensity-Modulated 15Docetaxel 12Nivolumab 11Paclitaxel 10Fluorouracil 10Carboplatin 8Radiosurgery 6epacadostat 5Radiation 5spartalizumab 4avelumab 4Surgical Procedures, Operative 4Radiotherapy, Conformal 4Immunoglobulin G 4Biopsy 4ribociclib 3durvalumab 3bempegaldesleukin 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Everolimus 3Erlotinib Hydrochloride 3Disulfides 3Cyclophosphamide 3Albumin-Bound Paclitaxel 3utomilumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Squamous Cell Carcinoma of Head and Neck × talactoferrin alfa × Clear all
NCT01528137 2016-08-02

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Stanford University

Phase 1 Terminated
4 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡